1. The Review on Antimicrobial Resistance (Chaired by Jim OʼNeill). Tackling Drug- Resistant Infections Globally: Final Report and Recommendations. 2016;(May):1-80.
2. Johnson MD, Lewis RE, Dodds Ashley ES, et al. Core recommendations for antifungal stewardship: a statement of the mycoses study group education and research consortium. J Infect Dis. 2020;222:S175-S198. doi:10.1093/INFDIS/JIAA394
3. Valerio M, Muñoz P, Rodríguez CG, et al. Antifungal stewardship in a tertiary-care institution: A bedside intervention. Clin Microbiol Infect. 2015;21(5):492.e1-492.e9. doi:10.1016/j.cmi.2015.01.013
4. 深在性真菌症のガイドライン作成委員会 編. 真菌症フォーラム. 深在性真菌症の診断・治療ガイドライン2014 ⼩児領域改訂版. 2016.
5. Maeda M, Muraki Y, Kosaka T, et al. The first nationwide survey of antimicrobial stewardship programs conducted by the Japanese Society of Chemotherapy. J Infect Chemother. 2019;25(2):83-88. doi:10.1016/j.jiac.2018.11.001
6. Imataki O, Kami M, Kim SW, et al. A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant. 2004;33(12):1173-1179. doi:10.1038/sj.bmt.1704526
7. Samura M, Hirose N, Kurata T, et al. Support for fungal infection treatment mediated by pharmacist-led antifungal stewardship activities. J Infect Chemother. 2020;26(3):272- 279. doi:10.1016/j.jiac.2019.09.016
8. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. National surveillance of species distribution in blood isolates of Candida species in Japan and thier susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother. 2004;53(2):283-289. doi:10.1093/jac/dkh053
9. Kakeya H, Yamada K, Kaneko Y, et al. National trends in the distribution of candida species causing candidemia in Japan from 2003 to 2014: A report by the epidemiological investigation committee for human mycoses in Japan. Med Mycol J. 2018;59(1):E19-E22. doi:10.3314/mmj.17-00014
10. Sakagami T, Kawano T, Yamashita K, et al. Antifungal susceptibility trend and analysis of resistance mechanism for Candida species isolated from bloodstream at a Japanese university hospital. J Infect Chemother. 2019;25(1):34-40. doi:10.1016/j.jiac.2018.10.007
11. Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-2016. Open Forum Infect Dis. 2019;6(Suppl 1):S79-S94. doi:10.1093/ofid/ofy358
12. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med. 2015;373(15):1445- 1456. doi:10.1056/NEJMra1315399
13. Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: A prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother. 2011;55(2):532-538. doi:10.1128/AAC.01128-10
14. Arendrup MC, Sulim S, Holm A, et al. Diagnostic issues, clinical characteristics, and outcomes for patients with fungemia. J Clin Microbiol. 2011;49(9):3300-3308. doi:10.1128/JCM.00179-11
15. Nagao M. A multicentre analysis of epidemiology of the nosocomial bloodstream infections in Japanese university hospitals. Clin Microbiol Infect. 2013;19(9):852-858. doi:10.1111/1469-0691.12083
16. Almirante B, Rodríguez D, Cuenca-Estrella M, et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream infections: Case-control population-based surveillance study of patients in Barcelona, Spain, from 2002 to 2003. J Clin Microbiol. 2006;44(5):1681-1685. doi:10.1128/JCM.44.5.1681-1685.2006
17. Kato H, Yoshimura Y, Suido Y, et al. Mortality and risk factor analysis for Candida blood stream infection: A multicenter study. J Infect Chemother. 2019;25(5):341-345. doi:10.1016/j.jiac.2019.01.002
18. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial Bloodstream Infections in US Hospitals: Analysis of 24,179 Cases from a Prospective Nationwide Surveillance Study. Clin Infect Dis. 2004;39(3):309-317. doi:10.1086/421946
19. Fukuoka T, Johnston DA, Winslow CA, et al. Genetic basis for differential activities of fluconazole and voriconazole against Candida krusei. Antimicrob Agents Chemother. 2003;47(4):1213-1219. doi:10.1128/AAC.47.4.1213-1219.2003
20. ⼀般社団法人 日本医真菌学会 編. 侵襲性カンジダ症に対するマネジメントのための臨床実践ガイドライン. 2021.
21. Bizerra FC, Jimenez-Ortigosa C, Souza ACR, et al. Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin. Antimicrob Agents Chemother. 2014;58(4):2438-2440. doi:10.1128/AAC.02189-13
22. Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2015;62(4):e1-e50. doi:10.1093/cid/civ933
23. Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients. Clin Microbiol Infect. 2012;18(SUPPL.7):19-37. doi:10.1111/1469-0691.12039
24. Ullmann AJ, Akova M, Herbrecht R, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: Adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin Microbiol Infect. 2012;18(SUPPL.7):53-67. doi:10.1111/1469-0691.12041
25. Tashiro S, Osa S, Igarashi Y, et al. Echinocandins versus non-echinocandins for the treatment of invasive candidiasis: A meta-analysis of randomized controlled trials. J Infect Chemother. 2020;26(11):1164-1176. doi:10.1016/j.jiac.2020.06.008
26. Japan Society for Hematopoietic Cell Transplantation (JSHCT) guideline for prophylaxis and treatment of fungal infection. JSHCT monograph Vol 46. September, 2017.
27. Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45(6):737-779. doi:10.1007/s15010-017-1042-z
28. Kawabe A, Muraki Y, Inose R, et al. Trends of Antifungal Use Based on Sales Data in Japan from 2006 to 2015. Biol Pharm Bull. 2020;43(8):1248-1252. doi:10.1248/bpb.b20- 00302
29. Forrest GN, Weekes E, Johnson JK. Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect. 2008;56(2):126-129. doi:10.1016/j.jinf.2007.10.014
30. Perlin DS. Echinocandin Resistance in Candida. Clin Infect Dis. 2015;61(Suppl 6):S612- S617. doi:10.1093/cid/civ791
31. Clinical and Laboratory Standards Institute. M60: Performance Standards for Antifungal Susceptibility Testing of Yeasts; Supplement̶1st ed.; CLSI: Wayne, PA, USA, 2017.
32. Vallabhaneni S, Baggs J, Tsay S, Srinivasan AR, Jernigan JA, Jackson BR. Trends in antifungal use in US hospitals, 2006‒12. J Antimicrob Chemother. 2018;73(10):2867- 2875. doi:10.1093/jac/dky270
33. Taplitz RA, Kennedy EB, Flowers CR. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update summary. J Oncol Pract. 2018;14(11):692-695. doi:10.1200/JOP.18.00366
34. Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: Summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221-3230. doi:10.1093/jac/dky286
35. Fleming S, Yannakou CK, Haeusler GM, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44(12):1283-1297. doi:10.1111/imj.12595
36. Garnacho-Montero J, Díaz-Martín A, García-Cabrera E, et al. Risk factors for fluconazole-resistant candidemia. Antimicrob Agents Chemother. 2010;54(8):3149-3154. doi:10.1128/AAC.00479-10
37. Andes DR, Diekema DJ, Pfaller MA, Marchillo K, Bohrmueller J. In vivo pharmacodynamic target investigation for micafungin against Candida albicans and C. glabrata in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2008;52(10):3497-3503. doi:10.1128/AAC.00478-08
38. Andes D, Ambrose PG, Hammel JP, et al. Use of pharmacokinetic-pharmacodynamic analyses to optimize therapy with the systemic antifungal micafungin for invasive candidiasis or candidemia. Antimicrob Agents Chemother. 2011;55(5):2113-2121. doi:10.1128/AAC.01430-10
39. Kapralos I, Mainas E, Neroutsos E, et al. Population pharmacokinetics of micafungin over repeated doses in critically ill patients: a need for a loading dose? J Pharm Pharmacol. 2020;72(12):1750-1760. doi:10.1111/jphp.13353
40. Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018;97(2):197-207. doi:10.1007/s00277-017-3196-2
41. Teng JC, Slavin MA, Teh BW, et al. Epidemiology of invasive fungal disease in lymphoproliferative disorders. Haematologica. 2015;100(11):e462-6. doi:10.3324/haematol.2015.126698
42. Togano T, Suzuki Y, Nakamura F, Tse W, Kume H. Epidemiology of visceral mycoses in patients with acute leukemia and myelodysplastic syndrome: Analyzing the national autopsy database in Japan. Med Mycol. 2021;59(1):50-57. doi:10.1093/mmy/myaa029
43. Kontoyiennis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: Overview of the transplant- associated infection surveillance network (TRANSNET) database. Clin Infect Dis. 2010;50(8):1091-1100. doi:10.1086/651263
44. Zonios DI, Bennett JE. Update on azole antifungals. Semin Respir Crit Care Med. 2008;29(2):198-210. doi:10.1055/s-2008-1063858
45. Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845-851. doi:10.1056/NEJM199203263261301
46. Cornely OA, Ullmann AJ, Karthaus M. Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood. 2003;101(9):3365-3372. doi:10.1182/blood-2002-05-1356
47. Cojutti PG, Lugano M, Righi E, et al. Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp. Eur J Clin Pharmacol. 2018;74(11):1449-1459. doi:10.1007/s00228-018-2526-1
48. Aoyama T, Hirata K, Hirata R, et al. Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients. J Clin Pharm Ther. 2012;37(3):356-363. doi:10.1111/j.1365-2710.2011.01297.x
49. Alobaid AS, Wallis SC, Jarrett P, et al. Effect of obesity on the population pharmacokinetics of fluconazole in critically Ill patients. Antimicrob Agents Chemother. 2016;60(11):6550-6557. doi:10.1128/AAC.01088-16
50. Mclachlan AJ, Tett SE. Pharmacokinetics of fluconazole in people with HIV infection: A population analysis. Br J Clin Pharmacol. 1996;41(4):291-298. doi:10.1046/j.1365- 2125.1996.03085.x
51. Han S, Kim J, Yim H, et al. Population pharmacokinetic analysis of fluconazole to predict therapeutic outcome in burn patients with candida infection. Antimicrob Agents Chemother. 2013;57(2):1006-1011. doi:10.1128/AAC.01372-12
52. Roberts JA, Joynt GM, Choi GYS, Gomersall CD, Lipman J. How to optimise antimicrobial prescriptions in the Intensive Care Unit: Principles of individualised dosing using pharmacokinetics and pharmacodynamics. Int J Antimicrob Agents. 2012;39(3):187-192. doi:10.1016/j.ijantimicag.2011.11.002
53. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: Implications for antibacterial dosing in the critically Ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000
54. Du Bois D, Du Bois EF. A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition. 1989;5(5):303-311; discussion 312.
55. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41. doi:10.1159/000180580
56. Matsuo S, Imai E, Horio M, et al. Revised Equations for Estimated GFR From Serum Creatinine in Japan. Am J Kidney Dis. 2009;53(6):982-992. doi:10.1053/j.ajkd.2008.12.034
57. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration- time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother. 2007;51(1):35-39. doi:10.1128/AAC.00474-06
58. Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: Time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat. 2010;13(6):180-195. doi:10.1016/j.drup.2010.09.002
59. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12 Suppl 3(Supplement_3):S318-26. doi:10.1093/clinids/12.supplement_3.s318
60. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob Agents Chemother. 1985;28(5):648-653. doi:10.1128/AAC.28.5.648
61. Shiba K, Saito A, Miyahara T. [Pharmacokinetic evaluation of fluconazole in healthy volunteers]. Jpn J Antibiot. 1989;42(1):17-30. http://www.ncbi.nlm.nih.gov/pubmed/2540363
62. Izumisawa T, Kaneko T, Soma M, et al. Augmented renal clearance of vancomycin in hematologic malignancy patients. Biol Pharm Bull. 2019;42(12):2089-2094. doi:10.1248/bpb.b19-00652
63. Romano S, Fdez De Gatta M, Calvo M V., Caballero D, Dominguez-Gil A, Lanao JM. Population pharmacokinetics of amikacin in patients with haematological malignancies. J Antimicrob Chemother. 1999;44(2):235-242. doi:10.1093/jac/44.2.235
64. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother. 1998;42(5):1105-1109. doi:10.1128/aac.42.5.1105
65. Lewis RE. Current concepts in antifungal pharmacology. Mayo Clin Proc. 2011;86(8):805-817. doi:10.4065/mcp.2011.0247
66. Matsumoto K, Ueno K, Yoshimura H, et al. Fluconazole-induced convulsions at serum trough concentrations of approximately 80 microg/mL. Ther Drug Monit. 2000;22(5):635-636. doi:10.1097/00007691-200010000-00022